(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 116.2MM | +12% |
Gross Profit | 81.5MM | +17% |
Cost Of Revenue | 34.7MM | +1% |
Operating Income | -11.8MM | -54% |
Operating Expenses | 93.3MM | -2% |
Net Income | -9MM | -62% |
R&D | 12.4MM | -11% |
G&A | 80.6MM | -1% |
Interest Expense | 3.2MM | +96% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the first quarter of 2024 after the market closes on Tuesday, May 7, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results.
Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.
Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the U.S. Food and Drug Administration (FDA) cleared its sacroiliac joint fusion device, which will be marketed as Nevro1, without the need to include the screw ("NevroFix™").
Despite convincing beats on its latest set of quarterly figures, the market wasn't all that impressed with the company's latest developments.
Nevro Corp. (NYSE:NVRO) Q4 2023 Earnings Call Transcript February 21, 2024 Nevro Corp. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.5. Nevro Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to Nevro’s Fourth […]
Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.
Q4 2023 Nevro Corp Earnings Call
Nevro (NVRO) delivered earnings and revenue surprises of 70% and 0.22%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?